Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant

被引:8
作者
Fatela-Cantillo, D.
Hinojosa-Perez, R.
Peralvo-Rodriguez, M. I.
Canedo, J. Serrano-Diaz
Gomez-Bravo, M. A.
机构
[1] Hosp Univ Virgen Del Rocio, Dept Clin Biochem, Emergency & Intens Care Unit, Seville 41013, Spain
[2] Hosp Univ Virgen Del Rocio, Surg Hepatopancreatobiliary Univ, Seville 41013, Spain
关键词
D O I
10.1016/j.transproceed.2006.08.076
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. Area under the curve (AUC) limited sampling strategies have been proposed to improve the efficiency of mycophenolic acid (MPA), treatment of the transplanted patient. Our objective was to develop a model in the initial phase of the transplantation that explains the variability in the pharmacokinetic behavior of MPA in the immediate posttransplant period, following treatment with mycophenolate mofetil (MMF) in adult liver transplantation. Methods. One hundred ten pharmacokinetic simplified sampling profiles were collected, including four samples over a 6-hour postdose interval, in over 60 patients treated with cyclosporine or tacrolimus, MMF, and steroids, combining Daclizumab in more than a third of the patients. For an enzyme-multiplied immunoassay technique method was established for MPA estimates. The correlation between the AUC and the plasma concentration points was established using a multiple linear regression with various equations for three different pharmacokinetic groups. Results. The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day. The single sample showing the greatest correlation with the MPA AUC was the one collected after 3 hours (r(2) = 0.575); 59.1% of profiles displayed a single peak with more than half showing a tmax >= 3 hours. Conclusions. This profile analysis during the first few weeks highlighted the problems in determining therapeutic targets. Profiles showing a double peak revealed the marked influence of the enterohepatic cycle on MPA concentrations during the initial phase.
引用
收藏
页码:2482 / 2485
页数:4
相关论文
共 20 条
[1]
Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia [J].
Atcheson, BA ;
Taylor, PJ ;
Kirkpatrick, CMJ ;
Duffull, SB ;
Mudge, DW ;
Pillans, PI ;
Johnson, DW ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :284-286
[2]
Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction [J].
Cantarovich, M ;
Tzimas, GN ;
Barkun, J ;
Deschenes, M ;
Alpert, E ;
Tchervenkov, J .
TRANSPLANTATION, 2003, 76 (01) :98-102
[3]
Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? [J].
Cox, VC ;
Ensom, MHH .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :137-157
[4]
Limited sampling strategy for mycophenolic acid area under the curve [J].
Filler, G ;
Mai, I .
THERAPEUTIC DRUG MONITORING, 2000, 22 (02) :169-173
[5]
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation [J].
Hale, MD ;
Nicholls, AJ ;
Bullingham, RES ;
Hené, R ;
Hoitsma, A ;
Squifflet, JP ;
Weimar, W ;
Vanrenterghem, Y ;
Van de Woude, FJ ;
Verpooten, GA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :672-683
[6]
Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy [J].
Le Guellec, C ;
Büchler, M ;
Giraudeau, B ;
Le Meur, Y ;
Gakoué, JE ;
Lebranchu, Y ;
Marquet, P ;
Paintaud, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (11) :805-811
[7]
Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients -: Is it necessary? [J].
Mourad, M ;
Wallemacq, P ;
König, J ;
de Frahan, EH ;
Eddour, DC ;
De Meyer, M ;
Malaise, J ;
Squifflet, JP .
CLINICAL PHARMACOKINETICS, 2002, 41 (05) :319-327
[8]
Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient [J].
Mudge, DW ;
Atcheson, BA ;
Taylor, PJ ;
Pillans, PI ;
Johnson, DW .
THERAPEUTIC DRUG MONITORING, 2004, 26 (04) :453-455
[9]
Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation:: Implications for therapeutic drug monitoring [J].
Oellerich, M ;
Shipkova, M ;
Schütz, E ;
Wieland, E ;
Weber, L ;
Tönshoff, B ;
Armstrong, VW .
THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :20-26
[10]
Pawinski T, 2002, CLIN CHEM, V48, P1497